DERUVO, CATERINA
 Distribuzione geografica
Continente #
AS - Asia 47
NA - Nord America 34
EU - Europa 30
SA - Sud America 12
AF - Africa 2
Totale 125
Nazione #
US - Stati Uniti d'America 32
SG - Singapore 19
IT - Italia 14
CN - Cina 10
BR - Brasile 8
HK - Hong Kong 7
VN - Vietnam 5
DE - Germania 4
FI - Finlandia 4
RU - Federazione Russa 3
AR - Argentina 2
FR - Francia 2
GB - Regno Unito 2
JO - Giordania 2
NP - Nepal 2
CA - Canada 1
CL - Cile 1
EC - Ecuador 1
ES - Italia 1
JM - Giamaica 1
KG - Kirghizistan 1
MA - Marocco 1
MY - Malesia 1
ZA - Sudafrica 1
Totale 125
Città #
Singapore 10
San Jose 7
Hong Kong 6
Sannicandro di Bari 5
Beijing 4
Helsinki 4
Ashburn 3
Bari 2
Dallas 2
Ho Chi Minh City 2
London 2
Amman 1
Bishkek 1
Blumenau 1
Boardman 1
Buenos Aires 1
Cape Town 1
Da Nang 1
Detroit 1
Düsseldorf 1
Falkenstein 1
Frankfurt am Main 1
Fremont 1
Guarapari 1
Haiphong 1
Houston 1
Itajaí 1
Jiaxing 1
Kenitra 1
Lauterbourg 1
Mogi Guaçu 1
Montreal 1
Nuremberg 1
Petaling Jaya 1
Piscataway 1
Porto Alegre 1
Portoviejo 1
Ramgram 1
Salt Lake City 1
San Francisco 1
Santa Clara 1
Santana do Ipanema 1
Santiago 1
Teotônio Vilela 1
Tulsa 1
Votuporanga 1
Zarqa 1
Totale 83
Nome #
Novel 6-alkyl-bridged 4-arylalkylpiperazin-1-yl derivatives of azepino[4,3-b]indol-1(2H)-one as potent BChE-selective inhibitors showing protective effects against neurodegenerative insults 78
Retrospective Clinical Investigation into the Association Between Abnormal Blood Clotting, Oral Anticoagulant Therapy, and Medium-Term Mortality in a Cohort of COVID-19 Patients 25
The potential of MAO inhibitors as chemotherapeutics in cancer: A literature survey 17
Investigating Amphoteric 3,4′-Biscoumarin-Based ortho-[(Dialkylamino)methyl]phenols as Dual MAO and ChE Inhibitors 13
Totale 133
Categoria #
all - tutte 465
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 465


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20241 0 0 0 0 0 0 0 0 0 1 0 0
2024/202525 2 0 0 0 2 0 6 3 2 1 4 5
2025/2026107 6 3 4 9 17 12 17 1 17 13 7 1
Totale 133